Please login to the form below

Not currently logged in
Email:
Password:

FDA rejects GSK and Xenoport's Horizant

GSK and XenoPort, have received a Complete Response letter from the US FDA relating to Horizant (gabapentin enacarbil)

GlaxoSmithKline (GSK) and XenoPort, have received a Complete Response letter from the US Food and Drug Administration (FDA) relating to Horizant (gabapentin enacarbil), an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

The two companies submitted a New Drug Application (NDA) for Horizant extended-release tablets, to the FDA in January 2009.

The FDA's Center of Drug Evaluation and Research issue Complete Response letters once a review is completed, but when there are questions outstanding that prevent the NDA from being approved.

In the case of Horizant, the FDA indicated that a preclinical finding of pancreatic acinar cell tumours in rats was of sufficient concern to prevent approval of Horizant for RLS at this time.

GSK and Xenoport are evaluating the Complete Response letter and will communicate their intended next steps to the FDA.

Horizant is developed from a variant of Pfizer's Nerontin (gabentin), used to control seizures in epilepsy patients. Similar preclinical findings to those for Horizant were known for gabapentin when the FDA approved its use for refractory epilepsy. However, the FDA state that the 'seriousness and severity of refractory epilepsy justified the potential risks'.

Gabapentin enacarbil is also being developed in partnership with Astellas Pharma for the potential treatment of Restless Legs Syndrome in Japan. 

18th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics